2020 年 5 月至 2022 年 2 月期间英格兰接种 COVID-19 疫苗后成人病例死亡风险的时间变化:一项全国性监测研究。

IF 8.8 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Journal of the Royal Society of Medicine Pub Date : 2024-06-01 Epub Date: 2023-12-14 DOI:10.1177/01410768231216332
Florence Halford, Kathryn Yates, Tom Clare, Jamie Lopez-Bernal, Meaghan Kall, Hester Allen
{"title":"2020 年 5 月至 2022 年 2 月期间英格兰接种 COVID-19 疫苗后成人病例死亡风险的时间变化:一项全国性监测研究。","authors":"Florence Halford, Kathryn Yates, Tom Clare, Jamie Lopez-Bernal, Meaghan Kall, Hester Allen","doi":"10.1177/01410768231216332","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Risk of death after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has fallen during the pandemic, largely due to immunity from vaccination. In England, the timing and extent of this reduction varied due to staggered eligibility during the primary vaccination campaign, based on age and clinical risk group. Duration of protection is less well understood. Our objective was to estimate the case fatality risk (CFR) by vaccination status and time since last dose during a period of widespread community testing, to better understand the impact of coronavirus disease 2019 (COVID-19) vaccination and duration of protection.</p><p><strong>Design: </strong>SARS-CoV-2 cases diagnosed between May 2020 and February 2022 were linked to vaccine records from the National Immunisation Management System. CFR was calculated as the proportion of cases that died of COVID-19 per the death certificate, aggregated by week of specimen and stratified by 10-year age band and vaccination status.</p><p><strong>Setting: </strong>England, UK.</p><p><strong>Participants: </strong>A total of 10,616,148 SARS-CoV-2 cases, aged ≥18 years, recorded by England's laboratory reporting system.</p><p><strong>Main outcome measures: </strong>Case fatality risk of COVID-19, stratified by age band and vaccination status.</p><p><strong>Results: </strong>Overall, a reduction in CFR was observed for all age bands, with a clear temporal link to when the age group became eligible for primary vaccination and then the first booster. CFR increased with age (0.3% 50-59 years; 1.2% 60-69; 4.7% 70-79; 16.3% 80+) and was highest in the unvaccinated - albeit a reduction was observed over time. The highest CFR was seen in the unvaccinated 80+ group prior to vaccination rollout (30.6%). CFR was consistently lowest in vaccinated populations within 6 months of last dose, yet increased after over 6 months elapsed since last dose, across all age bands.</p><p><strong>Conclusions: </strong>COVID-19 CFR reduced after vaccination, with the lowest CFR seen across all age bands when vaccinated up to 6 months prior to specimen date. This provides some evidence for continued booster doses in older age groups.</p>","PeriodicalId":17271,"journal":{"name":"Journal of the Royal Society of Medicine","volume":" ","pages":"202-211"},"PeriodicalIF":8.8000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11299124/pdf/","citationCount":"0","resultStr":"{\"title\":\"Temporal changes to adult case fatality risk of COVID-19 after vaccination in England between May 2020 and February 2022: a national surveillance study.\",\"authors\":\"Florence Halford, Kathryn Yates, Tom Clare, Jamie Lopez-Bernal, Meaghan Kall, Hester Allen\",\"doi\":\"10.1177/01410768231216332\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Risk of death after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has fallen during the pandemic, largely due to immunity from vaccination. In England, the timing and extent of this reduction varied due to staggered eligibility during the primary vaccination campaign, based on age and clinical risk group. Duration of protection is less well understood. Our objective was to estimate the case fatality risk (CFR) by vaccination status and time since last dose during a period of widespread community testing, to better understand the impact of coronavirus disease 2019 (COVID-19) vaccination and duration of protection.</p><p><strong>Design: </strong>SARS-CoV-2 cases diagnosed between May 2020 and February 2022 were linked to vaccine records from the National Immunisation Management System. CFR was calculated as the proportion of cases that died of COVID-19 per the death certificate, aggregated by week of specimen and stratified by 10-year age band and vaccination status.</p><p><strong>Setting: </strong>England, UK.</p><p><strong>Participants: </strong>A total of 10,616,148 SARS-CoV-2 cases, aged ≥18 years, recorded by England's laboratory reporting system.</p><p><strong>Main outcome measures: </strong>Case fatality risk of COVID-19, stratified by age band and vaccination status.</p><p><strong>Results: </strong>Overall, a reduction in CFR was observed for all age bands, with a clear temporal link to when the age group became eligible for primary vaccination and then the first booster. CFR increased with age (0.3% 50-59 years; 1.2% 60-69; 4.7% 70-79; 16.3% 80+) and was highest in the unvaccinated - albeit a reduction was observed over time. The highest CFR was seen in the unvaccinated 80+ group prior to vaccination rollout (30.6%). CFR was consistently lowest in vaccinated populations within 6 months of last dose, yet increased after over 6 months elapsed since last dose, across all age bands.</p><p><strong>Conclusions: </strong>COVID-19 CFR reduced after vaccination, with the lowest CFR seen across all age bands when vaccinated up to 6 months prior to specimen date. This provides some evidence for continued booster doses in older age groups.</p>\",\"PeriodicalId\":17271,\"journal\":{\"name\":\"Journal of the Royal Society of Medicine\",\"volume\":\" \",\"pages\":\"202-211\"},\"PeriodicalIF\":8.8000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11299124/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Royal Society of Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/01410768231216332\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/12/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Royal Society of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/01410768231216332","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:感染严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)后的死亡风险在大流行期间有所下降,这主要归功于疫苗接种产生的免疫力。在英格兰,由于在初级疫苗接种活动中,根据年龄和临床风险组别错开了接种资格,因此降低风险的时间和程度各不相同。人们对保护的持续时间了解较少。我们的目标是在广泛的社区检测期间,根据疫苗接种情况和最后一次接种后的时间估算病例死亡风险(CFR),以更好地了解冠状病毒病 2019 (COVID-19) 疫苗接种的影响和保护持续时间:设计:将 2020 年 5 月至 2022 年 2 月期间确诊的 SARS-CoV-2 病例与国家免疫管理系统中的疫苗接种记录联系起来。CFR是根据死亡证明中死于COVID-19的病例比例计算的,按标本周汇总,并按10岁年龄段和疫苗接种情况分层:地点:英国英格兰:英格兰实验室报告系统共记录了 10,616,148 例年龄≥18 岁的 SARS-CoV-2 病例:主要结果指标:COVID-19病例死亡风险,按年龄段和疫苗接种情况进行分层:结果:总体而言,所有年龄段的病死率都有所下降,这与该年龄段何时有资格接种初级疫苗以及何时接种第一次加强免疫有明显的时间联系。CFR随年龄的增长而增加(50-59岁为0.3%;60-69岁为1.2%;70-79岁为4.7%;80岁以上为16.3%),未接种者的CFR最高,尽管随着时间的推移CFR有所下降。在疫苗接种前,未接种疫苗的 80 岁以上人群的 CFR 最高(30.6%)。在所有年龄段中,最后一剂疫苗接种后6个月内接种人群的CFR始终最低,但在最后一剂疫苗接种后超过6个月后,CFR有所上升:结论:接种 COVID-19 后,CFR 有所下降,在标本采集日期前 6 个月内接种的人群中,CFR 在所有年龄段中最低。这为老年人继续接种加强剂提供了一些证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Temporal changes to adult case fatality risk of COVID-19 after vaccination in England between May 2020 and February 2022: a national surveillance study.

Objectives: Risk of death after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has fallen during the pandemic, largely due to immunity from vaccination. In England, the timing and extent of this reduction varied due to staggered eligibility during the primary vaccination campaign, based on age and clinical risk group. Duration of protection is less well understood. Our objective was to estimate the case fatality risk (CFR) by vaccination status and time since last dose during a period of widespread community testing, to better understand the impact of coronavirus disease 2019 (COVID-19) vaccination and duration of protection.

Design: SARS-CoV-2 cases diagnosed between May 2020 and February 2022 were linked to vaccine records from the National Immunisation Management System. CFR was calculated as the proportion of cases that died of COVID-19 per the death certificate, aggregated by week of specimen and stratified by 10-year age band and vaccination status.

Setting: England, UK.

Participants: A total of 10,616,148 SARS-CoV-2 cases, aged ≥18 years, recorded by England's laboratory reporting system.

Main outcome measures: Case fatality risk of COVID-19, stratified by age band and vaccination status.

Results: Overall, a reduction in CFR was observed for all age bands, with a clear temporal link to when the age group became eligible for primary vaccination and then the first booster. CFR increased with age (0.3% 50-59 years; 1.2% 60-69; 4.7% 70-79; 16.3% 80+) and was highest in the unvaccinated - albeit a reduction was observed over time. The highest CFR was seen in the unvaccinated 80+ group prior to vaccination rollout (30.6%). CFR was consistently lowest in vaccinated populations within 6 months of last dose, yet increased after over 6 months elapsed since last dose, across all age bands.

Conclusions: COVID-19 CFR reduced after vaccination, with the lowest CFR seen across all age bands when vaccinated up to 6 months prior to specimen date. This provides some evidence for continued booster doses in older age groups.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.40
自引率
3.50%
发文量
107
审稿时长
6-12 weeks
期刊介绍: Since 1809, the Journal of the Royal Society of Medicine (JRSM) has been a trusted source of information in the medical field. Our publication covers a wide range of topics, including evidence-based reviews, original research papers, commentaries, and personal perspectives. As an independent scientific and educational journal, we strive to foster constructive discussions on vital clinical matters. While we are based in the UK, our articles address issues that are globally relevant and of interest to healthcare professionals worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信